$0.41
+0.01 (+3.05%)
Open$0.41
Previous Close$0.40
Day High$0.42
Day Low$0.40
52W High$2.75
52W Low$0.23
Volume—
Avg Volume463.3K
Market Cap8.05M
P/E Ratio—
EPS$-2.75
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+9,114.2% upside
Current
$0.41
$0.41
Target
$37.99
$37.99
$25.94
$37.99 avg
$62.46
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 38.53M | 30.53M | 257.5K |
| Net Income | -77,381,167 | -55,180,294 | -16,876 |
| Profit Margin | -200.8% | -190.8% | -6.6% |
| EBITDA | -77,826,512 | -58,581,084 | -21,131 |
| Free Cash Flow | — | — | -13,268 |
| Rev Growth | +26.2% | +26.2% | +2.0% |
| Debt/Equity | 0.08 | 0.08 | 0.31 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $264.34 | -0.29% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $414.61 | +2.11% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $150.93 | +0.83% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $526.19 | +0.73% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $788.04 | -1.00% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.96 | +2.55% | 41.4 | 33.44B |